Yuhuan Zheng

Discrepancies between clinical staging and pathological findings of operable cervical carcinoma with stage IB-IIB: a retrospective analysis of 818 patients.

Chemokines CCL2, 3, 14 stimulate macrophage bone marrow homing, proliferation, and polarization in multiple myeloma.

PIG7 promotes leukemia cell chemosensitivity via lysosomal membrane permeabilization.

Role of Myeloma-Derived MIF in Myeloma Cell Adhesion to Bone Marrow and Chemotherapy Response.

Microarray-based analysis and clinical validation identify ubiquitin-conjugating enzyme E2E1 (UBE2E1) as a prognostic factor in acute myeloid leukemia.

High-expressing cystic fibrosis transmembrane conductance regulator interacts with histone deacetylase 2 to promote the development of Ph+ leukemia through the HDAC2-mediated PTEN pathway.

High CFTR expression in Philadelphia chromosome-positive acute leukemia protects and maintains continuous activation of BCR-ABL and related signaling pathways in combination with PP2A.

Therapeutic effects of CSF1R-blocking antibodies in multiple myeloma.

Chidamide and decitabine can synergistically induce apoptosis of Hodgkin lymphoma cells by up-regulating the expression of PU.1 and KLF4.

Combination of IKZF1 deletion and early molecular response show significant roles on prognostic stratification in Philadelphia chromosome-positive acute lymphoblastic leukemia patients.

Prognostic value of diametrically polarized tumor-associated macrophages in multiple myeloma.

Young female patients with multiple myeloma have low occurrence of osteolytic lesion.

Correction: Chidamide and decitabine can synergistically induce apoptosis of Hodgkin lymphoma cells by up-regulating the expression of PU.1 and KLF4.

Hypoxia with Wharton's jelly mesenchymal stem cell coculture maintains stemness of umbilical cord blood-derived CD34 cells.

SLC2A5 overexpression in childhood philadelphia chromosome-positive acute lymphoblastic leukaemia.

The Correlation of Symptom Clusters and Functional Performance in Adult Acute Leukemia Patients Under Chemotherapy.

PIM3 Promotes the Proliferation and Migration of Acute Myeloid Leukemia Cells.

Low-dose ruxolitinib shows effective in treating myelofibrosis.

Homoharringtonine synergizes with quizartinib in FLT3-ITD acute myeloid leukemia by targeting FLT3-AKT-c-Myc pathway.

BMI1 regulates multiple myeloma-associated macrophage's pro-myeloma functions.

The Feasibility and Efficacy of Self-help Relaxation Exercise in Symptom Distress in Patients With Adult Acute Leukemia: A Pilot Randomized Controlled Trial.

Prognostic significance of p53, Sox11, and Pax5 co-expression in mantle cell lymphoma.

Intratumor Heterogeneity of MIF Expression Correlates With Extramedullary Involvement of Multiple Myeloma.

ALCAM-EGFR interaction regulates myelomagenesis.

Minimal residual disease in multiple myeloma: current status.

Differential mA RNA landscapes across hematopoiesis reveal a role for IGF2BP2 in preserving hematopoietic stem cell function.

Circulating exosomal microRNAs as diagnostic and prognostic biomarkers in patients with diffuse large B-cell lymphoma.

Cancer-Cell-Biomimetic Nanoparticles for Targeted Therapy of Multiple Myeloma Based on Bone Marrow Homing.

The expression and clinical significance of programmed cell death receptor 1 and its ligand in tumor tissues of patients with extranodal nasal NK/T cell lymphoma.

Estrogen-Responsive Gene MAST4 Regulates Myeloma Bone Disease.

ALCAM regulates multiple myeloma chemoresistant side population.

Symptom clusters and quality of life in ambulatory patients with multiple myeloma.

Compassion satisfaction and compassion fatigue in haematology cancer nurses: A cross-sectional survey.

Pathogenesis and treatment of multiple myeloma.

Dasatinib and interferon alpha synergistically induce pyroptosis-like cell death in philadelphia chromosome positive acute lymphoblastic leukemia.

ISG20L2 suppresses bortezomib antimyeloma activity by attenuating bortezomib binding to PSMB5.

A novel immune prognostic model of non-M3 acute myeloid leukemia.

A stratified therapeutic model incorporated with studies on regulatory B cells for elderly patients with newly diagnosed multiple myeloma.

Liposome-Encapsulated Melphalan Exhibits Potent Antimyeloma Activity and Reduced Toxicity.

A systematic review on performance analysis of critical time points in multiple myeloma treated by CAR-T cell immunotherapy.

Treatment attrition rates and relevant risk factors in multiple myeloma: A real-world study in China.

Optimal timing and drug combination of selinexor in multiple myeloma: a systematic review and meta-analysis.

Combinations of ivermectin with proteasome inhibitors induce synergistic lethality in multiple myeloma.

[Progress in Chimeric Antigen Receptor-Modified Natural Killer Cells for Multiple Myeloma].

Efficacy and safety of histone deacetylase inhibitors in peripheral T-cell lymphoma: a systematic review and meta-analysis on prospective clinical trials.

[Advances in Modeling of Multiple Myeloma in Mice].

Methylcrotonyl-CoA carboxylase subunit 1 (MCCA) regulates multidrug resistance in multiple myeloma.

RNA-binding protein hnRNPU regulates multiple myeloma resistance to selinexor.

Influencing factors of cancer-related fatigue in acute leukemia patients: A cross-sectional study.

Daratumumab-based immunotherapy vs. lenalidomide, bortezomib and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: a systemic review.

Decreased RNA-binding protein heterogeneous nuclear ribonucleoprotein U improves multiple myeloma sensitivity to lenalidomide.

Single-cell sequencing reveals the correlation of aggrephagy signaling and multiple myeloma immune microenvironment composition.

Phase I study of TQB3602, an oral proteasome inhibitor, in relapsed and refractory multiple myeloma.

Intravascular large B-cell lymphoma as a covert trigger for hemophagocytic lymphohistiocytosis complicated with capillary leak syndrome: a case report and literature review.

Maintenance therapy for cytogenetically high-risk multiple myeloma: landscape in the era of novel drugs.

Dihydrolipoamide dehydrogenase (DLD) is a novel molecular target of bortezomib.

A predictive risk-scoring model for survival prognosis of multiple myeloma based on gain/amplification of 1q21: Experience in a tertiary hospital in South-Western China.

Modest survival benefits of autologous stem cell transplantation in multiple myeloma with renal impairment: a critical appraisal of the pre-antibody era.

Ferroptosis-related prognostic model of mantle cell lymphoma.

COMMD3 Regulates Copper Metabolism via the ATOX1-ATP7A-LOX Axis to Promote Multiple Myeloma Progression.